BioCryst Pharmaceuticals Inc (BCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
BioCryst Pharmaceuticals Inc (BCRX) Stock Forecast
Analysts expect BioCryst Pharmaceuticals (BCRX) to earn $0.87 per share in the fiscal year ending Dec 31, 2026, on revenue of $718.43M. Of 11 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 18.2% |
| Buy | 7 | 63.6% |
| Hold | 2 | 18.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 1.1% and revenue estimates rise 2.5%.
- Fiscal year ending Dec 31, 2026
- $0.87
- EPS consensus, revenue $718.43M
- Fiscal year ending Dec 31, 2027
- $0.86
- EPS consensus, revenue $736.06M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.87 | $0.85 to $0.88 | 2 | $718.43M | $714.07M to $727.03M | 10 |
| Dec 31, 2027 | $0.86 | $0.81 to $0.90 | 2 | $736.06M | $674.99M to $800.40M | 9 |
Quarterly Estimates
The EPS consensus rises from $0.08 for the quarter ending Dec 31, 2026 to $0.18 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.08 | $0.02 to $0.17 | 12 | $168.16M | $155.94M to $181.48M | 12 |
| Mar 31, 2027 | $0.18 | $0.17 to $0.18 | 2 | $166.91M | $159.99M to $172.20M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 16.0% from $0.75.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.87 | $0.75 | $0.75 | $0.75 | $0.75 | +16.1% |
| Fiscal year ending Dec 31, 2027 | $0.86 | $0.83 | $0.94 | $0.94 | $0.94 | -9.0% |
| Quarter ending Mar 31, 2027 | $0.18 | $0.16 | $0.15 | $0.15 | $0.15 | +16.7% |
Frequently Asked Questions About BCRX
What is the BCRX stock forecast?
Consensus analyst estimates put BioCryst Pharmaceuticals's EPS at $0.87 for the fiscal year ending Dec 31, 2026, on revenue of $718.43M. The consensus rating from 11 analysts is Buy.
How do analysts rate BCRX stock?
Of 11 analysts covering BioCryst Pharmaceuticals, 2 rate it Strong Buy, 7 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BCRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.87, with estimates from $0.85 to $0.88 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.86, with estimates from $0.81 to $0.90 from 2 analysts.
What revenue do analysts expect from BioCryst Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $718.43M, with estimates from $714.07M to $727.03M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $736.06M, with estimates from $674.99M to $800.40M.
How many analysts cover BCRX?
11 analysts rate BioCryst Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts